6月30日，Abivax S.A.盘中上涨36.68%，报131.53美元/股，成交额1.81亿美元。
消息面上，公司公布ABTECT维持试验Part 2积极数据：50mg obefazimod在诱导期未应答患者中实现37.2%临床缓解率及61.5%临床应答率；维持期复发患者重新用药后应答率和缓解率分别达69.7%和45.0%，且恶性肿瘤发生率与预期背景发生率一致，未出现新安全信号。此前50mg组曾因报告多例癌症病例致股价从130美元附近暴跌至约70美元，本次数据消除安全性新增隐患，前期争议逐步消化，多头情绪加速升温。此外，Wedbush将目标价从90美元上调至110美元。公司表示仍计划于第四季度向FDA提交新药上市申请。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.